Related references
Note: Only part of the references are listed.Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Meng-Ju Wu et al.
CANCER DISCOVERY (2022)
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Diana D. Shi et al.
CANCER CELL (2022)
Oncometabolite D-2HG alters T cell metabolism to impair CD8(+) T cell function
Giulia Notarangelo et al.
SCIENCE (2022)
CODEL: phase III study of RT, RT plus TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design
Kurt A. Jaeckle et al.
NEURO-ONCOLOGY (2021)
Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas
Timothy E. Richardson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2021)
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Martin J. van den Bent et al.
LANCET ONCOLOGY (2021)
Combination olaparib and durvalumab for patients with recurrent IDH-mutated gliomas.
Ronald Ramos et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI).
Francois Ducray et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas
Mirco Friedrich et al.
NATURE CANCER (2021)
Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
Ruichao Chai et al.
CANCER BIOLOGY & MEDICINE (2021)
Total copy number variation, somatic mutation burden, and histologic grade correlate with clinical outcome in oligodendroglioma
Timothy E. Richardson et al.
CLINICAL NEUROPATHOLOGY (2020)
INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.
Ingo K. Mellinghoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
Yuxiang Wang et al.
SCIENCE ADVANCES (2020)
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat et al.
NATURE (2020)
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
Ilgen Mender et al.
CANCER CELL (2020)
Oncometabolites suppress DNA repair by disrupting local chromatin signalling
Parker L. Sulkowski et al.
NATURE (2020)
Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells
Hiroaki Nagashima et al.
CANCER DISCOVERY (2020)
Inhibiting IDH mutations in low-grade glioma alters cellular function and the immune environment
Min Lu et al.
CANCER RESEARCH (2020)
Targeting IDH1-Mutated Malignancies with NRF2 Blockade
Yang Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
Felipe J. Nunez et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).
Sani Haider Kizilbash et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Total copy number variation as a prognostic factor in adult astrocytoma subtypes
Kanish Mirchia et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Lukas Bunse et al.
NATURE MEDICINE (2018)
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
Samuel K. McBrayer et al.
CELL (2018)
Mutant IDH1 regulates the tumor-associated immune system in gliomas
Nduka M. Amankulor et al.
GENES & DEVELOPMENT (2017)
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomase
Gary Kohanbash et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Correlation of immune phenotype with IDH mutation in diffuse glioma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2017)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity
Kensuke Tateishi et al.
CANCER RESEARCH (2017)
Oncometabolites D- and L-2-Hydroxyglutarate Inhibit the AIkB Family DNA Repair Enzymes under Physiological Conditions
Fangyi Chen et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2017)
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Yanxin Lu et al.
CANCER RESEARCH (2017)
Insulator dysfunction and oncogene activation in IDH mutant gliomas
William A. Flavahan et al.
NATURE (2016)
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2
Satoshi Inoue et al.
CANCER CELL (2016)
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment
Hinke F. van Thuijl et al.
ACTA NEUROPATHOLOGICA (2015)
Extreme Vulnerability of IDH1 Mutant Cancers to NAD plus Depletion
Kensuke Tateishi et al.
CANCER CELL (2015)
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Remco J. Molenaar et al.
CANCER RESEARCH (2015)
Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents
Pu Wang et al.
CELL REPORTS (2015)
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Jinlong Shi et al.
TUMOR BIOLOGY (2015)
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
J. Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Julie-Aurore Losman et al.
SCIENCE (2013)
MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations
Shani Mulholland et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Meghan J. Seltzer et al.
CANCER RESEARCH (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA
PA Aas et al.
NATURE (2003)
Reversal of DNA alkylation damage by two human dioxygenases
T Duncan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
